Acorda Provides Financial and Pipeline Update for Third Quarter 2018

Pharmaceutical Investing

Acorda Therapeutics (Nasdaq:ACOR) provided a financial and pipeline update for the third quarter ended September 30, 2018. As quoted in the press release: “Acorda’s highest priority is preparing for the expected launch of Inbrija. Our market research indicates that healthcare professionals, patients and care partners consider OFF periods, or the re-emergence of Parkinson’s symptoms, to …

Acorda Therapeutics (Nasdaq:ACOR) provided a financial and pipeline update for the third quarter ended September 30, 2018.

As quoted in the press release:

“Acorda’s highest priority is preparing for the expected launch of Inbrija. Our market research indicates that healthcare professionals, patients and care partners consider OFF periods, or the re-emergence of Parkinson’s symptoms, to be one of the most significant unmet needs in Parkinson’s, and that they are enthusiastic about the prospect of an inhaled formulation of levodopa as a treatment option,” said Ron Cohen, M.D., Acorda’s President and CEO.

“We were disappointed and disagree with the decision of the Federal appeals court regarding Ampyra, and we have filed an en banc petition requesting review by the entire court. At the same time, we were prepared for that potential outcome, and our original projections had us well capitalized to fully fund the launch of Inbrija and to develop the ARCUS pipeline. We have taken several steps over the past year both to conserve and to increase cash. Based on these, as well as greater than forecasted Ampyra sales, we are in now in an even stronger financial position, and are increasing our guidance for both cash and Ampyra sales in 2018.”

Click here to read the full press release.

The Conversation (0)
×